ResearcherErasmus MCActive in the last 2 years
Marco Huberts
Matched on OpenAlex author ID A5050864612. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 4
2022: 1 paper · 2023: none · 2024: none · 2025: 2 papers
Papers 3
- Identifying gene expression signatures of oncolytic virus response in patient-derived pancreatic ductal adenocarcinoma organoids. Co-author DOI 10.1016/j.omton.2025.201064↗
- The use of pancreatic ductal adenocarcinoma 2D and 3D models to evaluate NDV infection, replication and induced cell death. Co-author DOI 10.1038/s41598-025-06023-8↗
- Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in a xenograft murine model for pancreatic … First author DOI 10.1016/j.heliyon.2022.e09915↗
Closest collaborators
The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Bernadette G. van den Hoogen · 3 shared papers, 2022–2025 · strength 0.79
- Paper The use of pancreatic ductal adenocarcinoma 2D and 3D models to evaluate NDV infection, replication and induced cell de… DOI 10.1038/s41598-025-06023-8↗
- Paper Identifying gene expression signatures of oncolytic virus response in patient-derived pancreatic ductal adenocarcinoma … DOI 10.1016/j.omton.2025.201064↗
- Paper Comparison between intratumoral and intravenously administered oncolytic virus therapy with Newcastle disease virus in … DOI 10.1016/j.heliyon.2022.e09915↗
- Elham Aïda Farshadi · 2 shared papers, 2025 · strength 0.61
- Paper The use of pancreatic ductal adenocarcinoma 2D and 3D models to evaluate NDV infection, replication and induced cell de… DOI 10.1038/s41598-025-06023-8↗
- Paper Identifying gene expression signatures of oncolytic virus response in patient-derived pancreatic ductal adenocarcinoma … DOI 10.1016/j.omton.2025.201064↗
- J. Fréderique de Graaf · 1 shared paper, 2022 · strength 0.17
- Casper H.J. van Eijck · 1 shared paper, 2022 · strength 0.17
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.